Praluent (alirocumab)

pCPA File Number: 20949

Negotiation Status:

Concluded with an LOI

Indication(s):

Primary hypercholesterolemia (non-familial and heterozygous familial)

Sponsor/Manufacturer:

Sanofi-Aventis Canada Inc.

CDA-AMC Project Number:

SR0469-000

pCPA Engagement Letter Issued:

2016-08-26

Negotiation Process Concluded:

2018-08-02